<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/50EC2B76-1B12-43D9-9D1E-469280159E88"><gtr:id>50EC2B76-1B12-43D9-9D1E-469280159E88</gtr:id><gtr:name>PhotoBiotics</gtr:name><gtr:address><gtr:line1>47 Princess Gate</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line3>South Kensington</gtr:line3><gtr:postCode>SW7 2QA</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/50EC2B76-1B12-43D9-9D1E-469280159E88"><gtr:id>50EC2B76-1B12-43D9-9D1E-469280159E88</gtr:id><gtr:name>PhotoBiotics</gtr:name><gtr:address><gtr:line1>47 Princess Gate</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line3>South Kensington</gtr:line3><gtr:postCode>SW7 2QA</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/89FDED97-2F7C-4D37-BE89-E8331A3C2D82"><gtr:id>89FDED97-2F7C-4D37-BE89-E8331A3C2D82</gtr:id><gtr:firstName>Laurence</gtr:firstName><gtr:surname>Lovat</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_13036"><gtr:id>41A7A832-BF45-4D2E-9C86-57A3AF6C4033</gtr:id><gtr:title>Biomedical Catalyst ? Antibody Directed Phototherapy for Oesophageal Adenocarcinoma</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MC_PC_13036</gtr:grantReference><gtr:abstractText>Oesophageal Cancer is rapidly rising and is the 4th largest cancer killer in men. This project supports combining PhotoBiotics' proprietary OptiLink technology and its own drugs with experts from Imperial College and University College London National Medical Laser Centre to develop a novel antibody-directed phototherapy (ADP) drug to treat cancer. These drugs have few side effects and tumours cannot develop drug resistance to them. We have identified a clinically-validated target and have preliminary data to show that we can tackle this for Oesophageal Cancer. Photobiotics will oversee the manufacture and testing of the drug, Imperial College will help to generate functional data and UCL will treat tumours using their established models. If successful, thus funding will lead to major interest from the pharmaceutical industry to take this into clinical trials.</gtr:abstractText><gtr:technicalSummary>Oesophageal Cancer is rapidly rising and is the 4th largest cancer killer in men. This project supports combining PhotoBiotics' proprietary OptiLink technology and its own drugs with experts from Imperial College and University College London National Medical Laser Centre to develop a novel antibody-directed phototherapy (ADP) drug to treat cancer. These drugs have few side effects and tumours cannot develop drug resistance to them. We have identified a clinically-validated target and have preliminary data to show that we can tackle this for Oesophageal Cancer. Photobiotics will oversee the manufacture and testing of the drug, Imperial College will help to generate functional data and UCL will treat tumours using their established models. If successful, thus funding will lead to major interest from the pharmaceutical industry to take this into clinical trials.</gtr:technicalSummary><gtr:fund><gtr:end>2015-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>0</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Photobiotics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Photobiotics</gtr:description><gtr:id>B239C3C9-0033-4F5D-86AE-D0D9B06B97C2</gtr:id><gtr:impact>Various abstracts to scientific meetings</gtr:impact><gtr:outcomeId>546475f52c2312.10704559-1</gtr:outcomeId><gtr:partnerContribution>They have made targeted antibodies conjugated to their proprietary photosensitisers.</gtr:partnerContribution><gtr:piContribution>We have done the in vivo work for targeted photodynamic therapy studies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Oral presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4E71EC4B-1244-4CD8-B756-E233B87274E7</gtr:id><gtr:impact>We run an annual national event which drew international faculty to present our findings both to researchers but also to lay members of the general public who have an interest in this subject</gtr:impact><gtr:outcomeId>58a0f991a9e809.43829659</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015,2016,2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>348095</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A low cost screening tool to replace endoscopy in patients with persistent heartburn</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Charles Wolfson Charitable Trust</gtr:fundingOrg><gtr:id>3A05632C-1B74-42D8-945D-8698598F6DA9</gtr:id><gtr:outcomeId>56dd6d23026590.23080468</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Specialist Advisor to NICE</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FC35EF8C-9A88-400A-958A-4A1A0D4567A3</gtr:id><gtr:impact>Approval of minimally invasive ablative therapy for treatment of dysplasia and early cancer in Barrett's oesophagus.</gtr:impact><gtr:outcomeId>5464786f83e599.05103828</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type><gtr:url>http://www.nice.org.uk/guidance/CG106</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Muc1-antibody directed photodynamic therapy agent</gtr:description><gtr:id>BC098F92-56A6-42C2-85AD-638A09CCCD89</gtr:id><gtr:impact>This is still under initial development but if it can be made to work, would create a whole new approach to targeted cancer therapy.</gtr:impact><gtr:outcomeId>5464942675c658.87009446</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Targeted PDT agent for oesophageal adenocarcinoma</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E8BC5DC6-4BDE-403D-BE67-F64126825E61</gtr:id><gtr:title>Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e756e2b267556caf4706832aa90154ae"><gtr:id>e756e2b267556caf4706832aa90154ae</gtr:id><gtr:otherNames>Paterson AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>542e7e287322c3.46914510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5106E6F-DFEB-42DA-98EE-8DA9C0306F28</gtr:id><gtr:title>Evaluation of TP53 Mutations on Barrett's Epithelium FFPE Specimens With a Novel Next Generation Sequencing Platform Highlights a Discordance With p53 Immunohistochemistry: Analysis of the Barrett's Epithelium Genome Investigation Study (BEGINS)</gtr:title><gtr:parentPublicationTitle>GASTROENTEROLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fa584a798f85ffae00f464a64c69237"><gtr:id>7fa584a798f85ffae00f464a64c69237</gtr:id><gtr:otherNames>Butt Mohammed A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>57fea823944586.62459658</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>109DA81A-2FDA-4AA7-9FC6-A2A1A77D77F4</gtr:id><gtr:title>PWE-182&amp;nbsp;The effect of nf?b pathway deregulation on the progression to oesophageal adenocarcinoma through aberrant BCL3 expression</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21d3ea1ee6fb3f1f3ca8fa6ca350158c"><gtr:id>21d3ea1ee6fb3f1f3ca8fa6ca350158c</gtr:id><gtr:otherNames>Puccio I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>57fea823b4d503.51379132</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C528030-DDDD-4E53-85E8-87BB26818B8B</gtr:id><gtr:title>THE DEVELOPMENT OF A NOVEL ENDOSCOPIC ORTHOTOPIC TUMOUR MODEL FOR OESOPHAGEAL CANCER</gtr:title><gtr:parentPublicationTitle>GUT</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de40bcf6b6c9ce98651821e7c443ebfd"><gtr:id>de40bcf6b6c9ce98651821e7c443ebfd</gtr:id><gtr:otherNames>Sehgal V.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>57fea825b5a5a1.67063555</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98A59BC2-09EB-4ED9-B6BD-D520A75E24A1</gtr:id><gtr:title>The Development of a Novel Endoscopic Orthotopic Tumour Model for Oesophageal Cancer</gtr:title><gtr:parentPublicationTitle>GASTROENTEROLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38d88374781a3589c503bcad4fd938c4"><gtr:id>38d88374781a3589c503bcad4fd938c4</gtr:id><gtr:otherNames>Sehgal Vinay</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>57fea827d96f66.80428030</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD1C7ADC-1DF9-4A24-BCEF-F581DD876684</gtr:id><gtr:title>PTH-172&amp;Acirc;&amp;nbsp;Expression patterns of human epidermal growth factor receptor proteins in early gastric cancer</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b351762b096d4ba884d333ecfd7d57b3"><gtr:id>b351762b096d4ba884d333ecfd7d57b3</gtr:id><gtr:otherNames>Arez M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>57fea827be3b04.55875573</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05F5A688-BEE8-4526-90FD-3B82422EC6B0</gtr:id><gtr:title>Squamous cell carcinoma after radiofrequency ablation for Barrett's dysplasia.</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/298bd82a41df0713643015baa1146172"><gtr:id>298bd82a41df0713643015baa1146172</gtr:id><gtr:otherNames>Zeki SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>542e7d5f2f2299.78172328</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4739C485-AB82-4F08-A29B-B11162A4728A</gtr:id><gtr:title>The Role of Ki67 Expression on Cellular Organisation Leading to Progression Towards Oesophageal Adenocarcinoma</gtr:title><gtr:parentPublicationTitle>JOURNAL OF PATHOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d5da8f483d71ea75a6bd857ea7cca0d"><gtr:id>6d5da8f483d71ea75a6bd857ea7cca0d</gtr:id><gtr:otherNames>Puccio I.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>57fea8260360c8.10268074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38853AB5-31C2-41F3-8191-57811ED94B7F</gtr:id><gtr:title>PTH-171&amp;Acirc;&amp;nbsp;Evaluation of TP53 mutations on barrett&amp;acirc;??s epithelium FFPE specimens with a novel next generation sequencing platform highlights a discordance with P53 immunohistochemistry: analysis of the barrett&amp;acirc;??s epithelium genome investigation study (begins)</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e61e54af47e6a7f0ea22a0b060da8f8b"><gtr:id>e61e54af47e6a7f0ea22a0b060da8f8b</gtr:id><gtr:otherNames>Butt M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>57fea825d4a9c8.06128998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA2A6CFF-193E-4B9A-9C6B-3C3C7C2BEC95</gtr:id><gtr:title>A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett's oesophagus.</gtr:title><gtr:parentPublicationTitle>Lasers in medical science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/591aef09fa71336429cfa6f2dd8e0114"><gtr:id>591aef09fa71336429cfa6f2dd8e0114</gtr:id><gtr:otherNames>Dunn JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0268-8921</gtr:issn><gtr:outcomeId>542e7e28a9e492.93782754</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCEE17F6-03F2-4094-ABAF-AC99AE311E01</gtr:id><gtr:title>Radiofrequency ablation for early oesophageal squamous neoplasia: outcomes form United Kingdom registry.</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81eaa2a50f48806b4c6e447478538f5d"><gtr:id>81eaa2a50f48806b4c6e447478538f5d</gtr:id><gtr:otherNames>Haidry RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>542e7d5f718107.92640820</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>144400A3-F7D5-4075-9B39-DCFC2261A734</gtr:id><gtr:title>Clonal selection and persistence in dysplastic Barrett's esophagus and intramucosal cancers after failed radiofrequency ablation.</gtr:title><gtr:parentPublicationTitle>The American journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/298bd82a41df0713643015baa1146172"><gtr:id>298bd82a41df0713643015baa1146172</gtr:id><gtr:otherNames>Zeki SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9270</gtr:issn><gtr:outcomeId>542e7d5f9c9143.64416734</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A2E97CC-C211-4EAF-BDF7-B15BA8C4B494</gtr:id><gtr:title>Evaluating the Relationship Between Clinicopathological Variables and Mortality in Patients With Esophagogastric Adenocarcinomas</gtr:title><gtr:parentPublicationTitle>GASTROENTEROLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fa584a798f85ffae00f464a64c69237"><gtr:id>7fa584a798f85ffae00f464a64c69237</gtr:id><gtr:otherNames>Butt Mohammed A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>57fea824ee06a0.08100810</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFF37EAF-B25A-4831-BE35-7B04D53BCE55</gtr:id><gtr:title>PWE-183&amp;nbsp;Survivin expression increases in the progression to oesophageal adenocarcinoma</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21d3ea1ee6fb3f1f3ca8fa6ca350158c"><gtr:id>21d3ea1ee6fb3f1f3ca8fa6ca350158c</gtr:id><gtr:otherNames>Puccio I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>57fea8251adcf4.52195212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1CEC9BD-1781-4894-8F6F-50E141EDE857</gtr:id><gtr:title>Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81eaa2a50f48806b4c6e447478538f5d"><gtr:id>81eaa2a50f48806b4c6e447478538f5d</gtr:id><gtr:otherNames>Haidry RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>542e7e27deae80.16967808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>023F7D3A-129C-4FF1-B275-A391A4115AB8</gtr:id><gtr:title>A HER2 selective theranostic agent for surgical resection guidance and photodynamic therapy.</gtr:title><gtr:parentPublicationTitle>Photochemical &amp; photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ac0f58a4a59812123879016faa85d56"><gtr:id>8ac0f58a4a59812123879016faa85d56</gtr:id><gtr:otherNames>Pye H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-905X</gtr:issn><gtr:outcomeId>58a0f4fa6d65b5.58396251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46BCCA58-BD1A-4B87-AD8F-134FAC8B5D17</gtr:id><gtr:title>Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/674e6a8a4d7513de7d1d0749f7f6495a"><gtr:id>674e6a8a4d7513de7d1d0749f7f6495a</gtr:id><gtr:otherNames>Adil Butt M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>5a9f0e1358ad84.45448211</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_13036</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>006DC612-6329-4D37-A540-5FB2CA634720</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>